Scalper1 News
For years, multiple sclerosis has been a field good for producing blockbuster drugs — and Roche looks to be the latest entrant in that clique, with strong trial results for its candidate ocrelizumab. And it’s coming into the market just as some of the leading players are starting to look vulnerable. Roche’s (RHHBY) U.S. biotech division Genentech presented results from two phase-three trials of its drug ocrelizumab at the European Committee for Scalper1 News
Scalper1 News